Premium
Surgery as salvage therapy in chemotherapy‐resistant nonseminomatous germ cell tumours
Author(s) -
Ravi Ravi,
Duu Sheng Ong,
; Oliver,
Badenoch,
Fowler,
Hendry Hendry
Publication year - 1998
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1046/j.1464-410x.1998.00346.x
Subject(s) - salvage therapy , germ cell , chemotherapy , medicine , surgery , biology , biochemistry , gene
Objective To review our experience of surgical staging for residual masses after chemotherapy in patients with nonseminomatous germ cell tumour (NSGCT) and positive tumour markers. Patients and methods Of 107 patients with metastatic NSGCTs treated surgically after chemotherapy from 1978 to 1995, 30 (median age 30.5 years, range 20–52) had positive tumour markers. These patients were reviewed and the outcome compared with 77 patients who had normal tumour marker values. Results Of the 77 patients with negative markers undergoing surgical/pathological staging, 71 (92%) became continuously disease‐free, including 37 of 50 (74%) with viable NSGCT in excised specimens. Seventeen of 30 (57%) with raised marker levels undergoing similar surgery for chemotherapy‐resistant tumour became disease‐free, including 11 of 22 with viable NSGCT in the excised specimens. Conclusion Although the outcome after surgery is better in patients with negative tumour markers, it is clear that surgery is curative for patients with localized chemotherapy‐resistant masses. There is a need for continued debate on the timing of salvage surgery and subsequent chemotherapy.